Arcellx

Arcellx R&D per Employee

Delisted

The R&D Spending per Employee of Arcellx (ACLX) as of Nov 20, 2026 is 754,119.62 USD. In the previous year, R&D Spending per Employee was 751,641.15 USD — a change of 0.33% (higher).

R&D per Employee

754,119.62USD

YoY

0.33%

Last updated:

R&D Spending per Employee of Arcellx is 2025 754,119.62 USD. R&D Spending per Employee of Arcellx was 2024 751,641.15 USD. It decreases by 0.33% higher compared to the previous year.

The Arcellx R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2018
29,244.02 USD
Jan 1, 2019
75,435.41 USD
Jan 1, 2020
119,885.17 USD
Jan 1, 2021
224,320.57 USD
Jan 1, 2022
715,574.16 USD
Jan 1, 2023
640,425.84 USD
Jan 1, 2024
751,641.15 USD
Jan 1, 2025
754,119.62 USD
The Arcellx R&D per Employee history
YEARR&D per EmployeeYoY
754,119.62USD+0.33%
751,641.15USD+17.37%
640,425.84USD-10.50%
715,574.16USD+219.00%
224,320.57USD+87.11%
119,885.17USD+58.92%
75,435.41USD+157.95%
29,244.02USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Arcellx Stock analysis

What does Arcellx do? Arcellx, Inc develops innovative immunotherapies for cancer and incurable diseases, focusing on controllable cell therapies. The company's lead product CART-ddBCMA, a BCMA-targeting ddCAR therapy, is in a pivotal Phase II trial for relapsed or refractory multiple myeloma. Arcellx also advances two clinical-stage ARC-SparX programs: ACLX-001 for BCMA-targeting in multiple myeloma and ACLX-002 for CD123-targeting in acute myeloid leukemia and myelodysplastic syndrome. These therapies are developed using the company's D-Domain technology, with the goal of providing treatment options for patients with limited alternatives. Arcellx generates revenue through the development and clinical advancement of its cell therapy programs. The company's primary focus is on securing funding from strategic partnerships and clinical trial sponsorships to support its research and development activities. The key segments include patients with relapsed or refractory multiple myeloma, acute myeloid leukemia, and high-risk myelodysplastic syndrome, who are the target populations for its therapies. The company's lead program, CART-ddBCMA, is being evaluated in a pivotal Phase II trial, which is critical for advancing the therapy toward potential market approval. The firm's development pipeline includes CART-ddBCMA, ACLX-001, and ACLX-002, all leveraging the D-Domain technology for controllable cell therapies. Arcellx's business model centers on advancing these therapies through clinical trials to demonstrate efficacy and safety, with the ultimate goal of commercializing them for patients with unmet medical needs. The company's strategic partnerships and clinical trial sponsorships are essential for funding the progression of its programs from preclinical to clinical stages. Arcellx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Arcellx stock

R&D Spending per Employee of Arcellx is 754,119.62 USD in 2025.

R&D Spending per Employee of Arcellx changed from 751,641.15 USD to 754,119.62 USD, representing a 0.33% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Arcellx since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Arcellx historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Arcellx

All Key Metrics — Arcellx